US Stocks Move: Erasca plunges on September 23 due to competitor comparison, high-level correction, and small sample size.

Analysis of Erasca's Sharp Drop on September 23

Keywords: Competitor comparison, high-level pullback, small sample size

1. On September 22, 2026, Propanc released preclinical data for its pancreatic cancer candidate drug PRP, comparing its efficacy, mechanism of action, and development positioning with Erasca's ERAS-0015 Phase I data, forming comparative factors for projects under development for the same indication.

2. As of September 23, 2026, the company's cumulative increase since the beginning of the year remained at 288.71%, with a cumulative drop of 5.86% in the last five days. Against the backdrop of high trading levels, there is technical pullback and profit-taking pressure on the stock price.

3. On July 13, 2026, the company disclosed Phase I data of ERAS-0015 for pancreatic cancer. At a daily dose of 32 mg, the 8-week unconfirmed objective response rate was 57%, but the sample size was only 7 cases, and the repeatability of efficacy still requires further clinical data validation.

(Disclaimer: This content is generated by AI technology based on publicly available information. It is for reference only and does not constitute investment advice.)